We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Results of a New Human Recombinant Thrombin for the Treatment of Arterial Pseudoaneurysm.
- Authors
Malgor, Rafael D.; Labropoulos, Nicos; Gasparis, Antonios P.; Landau, David S.; Tassiopoulos, Apostolos K.
- Abstract
Objective: To evaluate the results of a new thrombin sealant (Recothrom) for the treatment of arterial pseudoaneurysms (PDAs). Methods: We reviewed 47 consecutive patients prospectively entered in a dedicated data set who underwent ultrasound-guided percutaneous thrombin injection to treat PDA. End points were PDA recurrence, need for reintervention, and related complications such as limb ischemia or allergic reactions. Results: Twenty-six patients were females (55%) and the median age of the entire group was 71 years (range, 45-87). The mean size of the PDA was 2.3 ± 0.9 cm. The mean injected volume was 2.4 ± 1.4 mL containing 500 ± 320 units. Recurrence of the PDA occurred in 4 (8.5%) patients and was not related to anticoagulation status, body habitus, platelets levels, or use of antiplatelets. All recurred PDAs were successfully sealed with a second (n = 3) and a third injection (n = 1). There was no distal embolization or allergic reactions and no surgical intervention was required. Conclusion: The new human recombinant thrombin (Recothrom) is a safer nonimmunogenic option with similar success rates of other fibrin glue sealants.
- Subjects
LONGITUDINAL method; HEALTH outcome assessment; RECOMBINANT proteins; DISEASE relapse; THROMBIN; COLOR Doppler ultrasonography; TREATMENT effectiveness; FALSE aneurysms; DATA analysis software; DESCRIPTIVE statistics; THERAPEUTICS
- Publication
Vascular & Endovascular Surgery, 2012, Vol 46, Issue 2, p145
- ISSN
1538-5744
- Publication type
Article
- DOI
10.1177/1538574411431346